Royalty Pharma (RPRX) Net Margin Growth (1y) (2020 - 2026)
Powered by 
Analysis
Royalty Pharma (RPRX) Net Margin Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -185.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -763.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 529.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 4,168.00 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 673.00 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2,208.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -392.00 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 29,636.00 |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | 166.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -392.00 |
| Mar 31, 2026 | -219.00 |
| Dec 31, 2025 | 90.00 |
| Sep 30, 2025 | -6,989.00 |
| Jun 30, 2025 | -2,017.00 |
| Mar 31, 2025 | 7,720.00 |
| Dec 31, 2024 | -6,406.00 |
| Sep 30, 2024 | 12,003.00 |
| Jun 30, 2024 | -2,910.00 |
| Mar 31, 2024 | -7,518.00 |
| Dec 31, 2023 | 22,821.00 |
| Sep 30, 2023 | -1,567.00 |
| Jun 30, 2023 | -2,644.00 |
| Mar 31, 2023 | 5,164.00 |
| Dec 31, 2022 | -11,715.00 |
| Sep 30, 2022 | 57.00 |
| Jun 30, 2022 | -5,365.00 |
| Mar 31, 2022 | -496.00 |
| Dec 31, 2021 | -5,476.00 |
| Sep 30, 2021 | -7,808.00 |